- JP-listed companies
- Perseus Proteomics Inc.
- Balance sheet
Perseus Proteomics Inc. (4882) Balance sheet
Market cap
¥2.6B
P/E ratio
Perseus Proteomics develops high-performance antibodies for cancer treatment and drug discovery using proprietary technology from the University of Tokyo.
| 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Cash and cash equivalents | - | 1,100 | 482 | 1,069 | 3,215 | 2,445 | 1,541 | 1,668 | 1,515 |
| Total current assets | - | 1,350 | 538 | 1,109 | 3,291 | 2,515 | 1,651 | 1,776 | 1,609 |
| Property, plant and equipment, net | - | - | - | - | - | - | - | - | - |
| Total non-current assets | - | 10 | 10 | 10 | 10 | 52 | 43 | 43 | 15 |
| Total assets | - | 1,360 | 548 | 1,119 | 3,301 | 2,567 | 1,694 | 1,819 | 1,624 |
| Total current liabilities | - | 33 | 62 | 35 | 148 | 111 | 129 | 125 | 65 |
| Total non-current liabilities | - | - | - | - | - | 59 | 166 | 262 | 340 |
| Total liabilities | - | 33 | 62 | 35 | 148 | 170 | 295 | 386 | 406 |
| Retained earnings | - | -530 | -1,371 | -413 | -1,012 | -1,799 | -2,904 | -3,809 | -718 |
| Stockholders' equity | 1,491 | 1,328 | 486 | 1,084 | 3,152 | 2,397 | 1,398 | 1,432 | 1,218 |